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Circulating Tumour Cells as an 
Independent Prognostic Factor 
in Patients with Advanced 
Oesophageal Squamous 
Cell Carcinoma Undergoing 
Chemoradiotherapy
Po-Jung Su1,*, Min-Hsien Wu1,2,3,*, Hung-Ming Wang1,*, Chia-Lin Lee4,5,6, Wen-Kuan Huang1,7,8, 
Chiao-En Wu1,9, Hsien-Kun Chang1, Yin-Kai Chao10, Chen-Kan Tseng11, Tzu-Keng Chiu2, 
Nina Ming-Jung Lin1, Siou-Ru Ye1, Jane Ying-Chieh Lee1 & Chia-Hsun Hsieh1,12
The role of circulating tumour cells (CTCs) in advanced oesophageal cancer (EC) patients undergoing 
concurrent chemoradiotherapy (CCRT) remains uncertain. A negative selection protocol plus flow 
cytometry was validated to efficiently identify CTCs. The CTC number was calculated and analysed 
for survival impact. The protocol’s efficacy in CTC identification was validated with a recovery rate 
of 44.6 ± 9.1% and a coefficient of variation of 20.4%. Fifty-seven patients and 20 healthy donors 
were enrolled. Initial staging, first response to CRT, and surgery after CRT were prognostic for overall 
survival, with P values of <0.0001, <0.0001, and <0.0001, respectively. The CTC number of EC 
patients is significantly higher (P = 0.04) than that of healthy donors. Multivariate analysis for disease-
specific progression-free survival showed that surgery after response to CCRT, initial stage, and CTC 
number (≥21.0 cells/mL) played independent prognostic roles. For overall survival, surgery after CCRT, 
performance status, initial stage, and CTC number were significant independent prognostic factors. 
In conclusion, a negative selection plus flow cytometry protocol efficiently detected CTCs. The CTC 
number before CCRT was an independent prognostic factor in patients with unresectable oesophageal 
squamous cell carcinoma. Further large-scale prospective studies for validation are warranted.
Oesophageal cancer (EC) is the 7th–8th most common cancer and is the 7th most common cause of death related 
to cancer in the United States1 and Europe2,3, and also in Asia, including Taiwan4. There are two main histological 
types of EC: squamous cell carcinoma (ESCC) and adenocarcinoma (EAC). Currently, the former type accounts 
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for the majority of cases of EC in African American, southern European, and Asian populations, whereas the 
incidence of the latter has tended to show gradual increases in the United States and northern Europe1–4. In EC 
that is unresectable or at locally advanced stages, regardless of the type, concurrent chemoradiotherapy (CCRT) 
has been the golden standard in treatment for decades5,6. Even in metastatic settings, palliative CCRT remains 
the main method of relieving symptoms resulting from cancer7,8. In recent years, several prognostic factors, such 
as the decreased number of lymph nodes after CCRT9, pathologic complete remission after CCRT and surgery10, 
and a history of heavy smoking11, have been found to be clinically prognostic in EC patients scheduled for CCRT. 
However, several biomarkers, such as microRNA (miRNA)12,13, NY-ESO-1 autoantibody14, and anti-P16 anti-
body15, are under investigation and awaiting large-scale clinical trials for evaluation.
Circulating epithelial or tumour cells (CECs or CTCs), identified and of interest since 186916, are defined as 
cells expressing epithelial cell surface markers and/or tumour specific marker(s) and must simultaneously be 
excluded from red/white blood cells (RBCs/WBCs) in the circulation. These cells have been thought to be live 
cells shed from the primary tumour mass, which are cultivable17,18, have the potential to metastasise into distant 
organs19, promote thrombosis12, acquire resistance to anticancer drugs20–23, and have been proven to be prognos-
tic and predictive in patients with various kinds of solid tumours24–29. Even more, CTCs could also potentially 
guide anticancer therapies22,30. Development of a reliable method of detection or isolation of CTCs could repre-
sent a good biomarker or predictor before the initiation of anticancer treatment in cancer patients. The major 
limitation in the efficacy of CTC isolation has spurred advances in nanoscience31, biochips18,32, physiology31,33, 
chemistry, and novel surface markers34–36, as well as many new methods or devices37. Although the CellSearch® 
system was developed and approved by the US Food and Drug Administration (FDA) in 2004, there is still no 
standard method or protocol to identify or isolate CTCs because of the relatively low efficiency of detection to 
date. In our opinion, a cheap and easy-to-access protocol or device is urgently needed.
For EC patients, the role of CTCs remains unclear in the literature. Therefore, to elucidate the clinical relevance of 
CTCs in patients with locally advanced ESCC, which is the most common type of EC at diagnosis, we prospectively 
designed and conducted a trial in a single medical centre in Taiwan. In addition, we attempted to report the efficacy 
of a relatively easy-to-perform method for CTC detection to enhance the advances in the field of CTCs.
Material and Methods
Study Design. The study was designed to be a prospective observational study. We aimed to elucidate the 
clinical significance of baseline CTCs before CCRT of unresectable ESCC patients. To determine a cutoff of 
CTC number for further survival analysis, we designed to use the cutoff found by ROC curves with Youden test 
(Supplementary Table S1) in EC patients (n = 57) and healthy donors (n = 20) in this pilot study. The endpoints of 
the study were to find the correlations among baseline CTCs, progression-free survival (PFS), and overall survival 
(OS). Following treatment response, surgery, disease progression and death from any causes were documented 
for survival analysis. The analysis was done only after when more than half of the events have occurred. A score 
combining treatment response and baseline CTC categories was designed to be analysed for its prediction ability 
of cancer death.
Patient Enrolment. This study was conducted in a single medical centre, Chang Gung Memorial Hospital, 
in Linkou, Taiwan. The study protocol was approved by the Institutional Review Board of Chang Gung Memorial 
Hospital (approval ID: 101-2161C). All patients provided written informed consent for the ethically approved 
protocols. Eligible patients with histologically or cytopathologically confirmed ESCC were all medically unfit 
for surgery or had surgically unresectable, locally advanced (stage IIb–IV, American Joint Committee on Cancer 
[AJCC] 7th edition), or metastatic cancer at initial presentation. Other enrolment criteria included: (1) age ≥ 20 
years old; (2) patients who could understand and sign the informed consent by their own will; and (3) patients 
with adequate liver and renal function and WBC counts for anticancer therapies, especially for CCRT. Patients 
with synchronous cancer or prior cancers within 5 years, except for non-melanoma skin cancers and in situ 
cervical cancers, were excluded at enrolment. Disease staging and management followed the standard treatment 
protocols according to institutional guidelines. Blood samples were drawn within 7 days before the first dose of 
chemotherapy. Study results were reported following the REporting recommendations for tumour MARKer prog-
nostic studies (REMARK) guidelines38. All the methods were carried out in accordance with the relevant guide-
lines, including any relevant details. Examinations for initial staging and response evaluation included computed 
tomography (CT), pan-endoscopy, endoscopic ultrasonography (EUS), positron emission tomography (PET), 
and/or bronchoscopy, except in patients who initially had metastatic lesions on CT scans. EUS was performed 
with an ultrasonic miniprobe (UM2R/12 MHz or UM3R/20 MHz; Olympus, Inc., Tokyo, Japan). Following the 
standard treatment guidelines, CCRT and/or surgery were scheduled and delivered by the medical oncologists, 
radiation oncologists, and chest surgeons on the oesophageal tumour board at Chang Gung Memorial Hospital. 
Based on the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.0 guidelines, the treatment 
response, including complete remission (CR), partial response (PR), stable disease (SD), and progressive disease 
(PD), was determined by the multidisciplinary oesophageal tumour board.
Chemotherapy Regimens of Chemoradiotherapy. Two chemotherapy regimens of CCRT were sched-
uled. One was 5-fluorouracil (1,000 mg/m2/day, administered as a continuous infusion over a period of 96 h on 
days 1–4 and 29–33) plus cisplatin (75 mg/m2, administered as an intravenous infusion for 3 h on days 1–29), 
which was called the PF regimen. The other regimen was carboplatin (area under the curve of 2, weekly) plus 
paclitaxel (50–60 mg/m2, weekly) for 6 consecutive doses, which was called the TC regimen. Radiotherapy was 
administered either sequentially to PF chemotherapy on days 8–29 to a total dose of 30 Gy (200 cGy/fraction) or 
concurrently with TC chemotherapy to a total dose of 41.4 Gy (180 cGy/fraction).
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Clinical Assessment of Chemoradiotherapy Effectiveness and Consolidation Therapy for 
Patients Who Did Not Undergo Oesophagectomy. The clinical response to CCRT was determined 
based on the results of endoscopy and imaging findings (CT and oesophagography) at 5–6 weeks post-treatment. 
As of 2007, PET scans were used for both staging and restaging workups. The response was considered complete 
(cCR) in the presence of the following criteria: (1) no evidence of disease on CT scans and no increased tracer 
uptake on PET images; and (2) no stricture, no residual tumour nor ulcer identified by panendoscopy, and neg-
ative biopsy results. Endoscopic findings in cCR patients were further classified into three categories: (1) Scar: 
healing ulcer; (2) Other finding: other abnormal mucosal findings (e.g., mucosa tag, polypoid lesion, granular 
protruded lesions, erosion, and lugol-voiding lesions); and (3) Normal: patients who did not show any mucosal 
abnormality. In the absence of contraindications, oesophagectomy was scheduled in all patients. Eligibility for 
surgery was based on the following: (1) medical fitness for surgery, with absence of liver cirrhosis and/or heart 
failure (New York Heart Association class III or IV); (2) absence of tracheoesophageal fistula; and (3) no evidence 
of recurrent laryngeal nerve invasion. For patients who refused scheduled surgery after neoadjuvant chemora-
diotherapy (nCRT), another course of CRT, consisting of PF or TC chemotherapy, was given as consolidation 
therapy. The total radiation dose was 60 Gy.
Experiments for Efficiency of Detection and Patients’ Sample Analysis. CTC analysis was per-
formed using a protocol with combined negative selection and positive detection strategies. Briefly, the methods 
were (1) a negative selection protocol for effective RBC and leukocyte depletion with Ficoll isolation and a CD45 
depletion kit; and (2) flow cytometry to quantitatively identify the number of CTCs. The concept of the protocol 
is illustrated in Fig. 1a. For control and validation experiments with head and neck cancer cell lines, the details 
were described in the Supplementary file.
Statistical Analysis. The numbers of pre-CCRT CTCs in advanced EC patients and healthy donors were 
compared using box plots and the Mann-Whitney U test with two-sided significance. Factors influencing the 
survival of patients with EC were assessed by univariate and multivariate Cox proportional hazards regression 
analysis. Parameters with significance in univariate analysis were subjected to multivariate Cox regression analy-
sis. Disease-specific PFS was calculated from the date of CTC sampling, within 7 days before the start of CCRT, to 
the date of cancer-specific progression. OS was defined as the period from the date of CTC sampling to the date 
of death from any cause. The circulating tumour cell plus response (CTCR) score is defined as the summation of 
the CTC score (zero for CTC number less than 21.0 cells/mL; 1 for CTC number ≥ 21.0 cells/mL) and the score of 
the CCRT response (zero for CR; 1 for PR; 2 for SD; and 3 for PD). Statistical analysis was performed using SPSS 
for Windows (version 18, SPSS Inc., Chicago, IL, USA). A P value of 0.05 was considered statistically significant.
Results
The Protocol Efficiency, Recovery Rate, and Purity. The efficacy of the protocol in identifying CTCs 
was validated with a recovery rate of 44.6 ± 9.1% and a % coefficient of variation (CV) of 20.4% in cell line spiking 
experiments (n = 20). Blood samples from healthy individuals were used as a control group, and the recovery rate 
of flow cytometry was 71.1 ± 12.0% with a %CV of 16.8% (experiment n = 43, 20 individuals in total).
Patient Enrolment. Between December 2012 and December 2014, a total of 57 patients were enrolled after 
detailed introduction of the trial design, scientific goals, and inconvenience/risks of participation in the Division 
of Haematology-Oncology, Chang Gung Memorial Hospital in Linkou. Meanwhile, 20 healthy donors were also 
recruited as controls for the CTC analysis. Basic characteristics of the enrolled patients are shown in Table 1. 
Clinical information and survival data were updated until August 2015. The median age of the patients was 54 
(36–78) years old. The majority of tumours were of the moderately differentiated type (68.4%), and the most 
frequent tumour locations in our population were the middle (36.8%) and upper part (36.1%) of the oesophagus. 
In addition, most patients scored an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1 
(61.4%), whereas the other 38.6% scored ≥ 2.
The Impacts of Initial Staging and Surgery After Chemoradiotherapy. Figure 2a–d demonstrates 
the prognostic survival impact of the initial AJCC (7th edition) staging, first treatment response to CRT, surgery 
after CRT, and undergoing surgery, with the exception of patients with initial T4b and M1 status, with P values of 
< 0.0001, < 0.0001, < 0.0001, and 0.005, respectively. In patients with imaging CR, PR, SD, and PD to CCRT, the 
median OS values were not reached, 15.9, 7.7, and 4.2 months, respectively, with a log rank test P value of < 0.001.
Figure 1. Illustration of circulating tumour cell (CTC) detection protocol. 
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Clinical Relevance of Circulating Tumour Cells Before Chemoradiotherapy. The CTC numbers 
of patients with EC (n = 57) were significantly higher (Mann-Whitney T test; P = 0.04) than those of healthy 
donors (n = 20) (Fig. 3a). A cutoff of 21.0 cells/mL with a sensitivity of 52.6% and a specificity of 80.0% was 
obtained by ROC curve (details in Supplementary Table S1) to differentiate EC patients from healthy individuals. 
After cox-proportional hazards model was examined, the following analysis showed that the CTC number before 
n %
Age, median (range), years 54 (36–78)
Gender, M/F 55/2
Histology
 Squamous cell carcinoma 57 100.00%
ECOG PS
 0–1 35 61.4%
 ≥ 2 22 38.6%
Differentiation of Cancer
 Well differentiated 3 5.3%
 Moderately differentiated 39 68.4%
 Poorly differentiated 15 26.3%
Tumour Location
 Cervical 5 8.8%
 Upper third 20 35.1%
 Middle third 21 36.8%
 Lower third 11 19.3%
Chemotherapy Regimen of CCRT
 Cisplatin plus 5-fluorouracil 37 64.9%
 Carboplatin plus paclitaxel 20 35.1%
Table 1.  Basic Characteristics of Enrolled Patients. Abbreviations: M/F, male/female; ECOG PS, Eastern 
Cooperative Oncology Group performance status; CCRT, concurrent chemoradiotherapy.
Figure 2. The correlations among tumour staging, response, surgery, unresectable status and survival. 
Panel A demonstrates that initial TNM staging correlates with overall survival (OS). Treatment response after 
concurrent chemoradiotherapy (CCRT) also correlates with OS (Panel B). Residual tumour with or without 
surgery is also highly prognostic for OS (Panel C); patients with initial T4b and M1 status are excluded (Panel D).
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CCRT can serve as a prognostic factor for disease-specific PFS and OS in patients with advanced squamous cell 
carcinoma with log rank test P values of 0.041 and 0.021, respectively (Fig. 3b,c). In multivariate analysis for 
disease-specific progression, surgery after response to CCRT, initial AJCC TNM stage, and CTC number (≥ 21.0 
cells/mL) were found to be independent prognostic factors with P values of 0.001, < 0.001, and 0.004, respectively 
(Table 2). In multivariate analysis for OS, surgery after response to CCRT, ECOG performance status, initial 
TNM stage (AJCC 7th edition), and CTC number were found to be independent prognostic factors with P values 
of < 0.001, < 0.001, 0.003, and 0.028, respectively (Table 2). Cancer location and chemotherapy regimen did not 
impact the OS (P = 0.515 and 0.136, respectively; Supplementary Figure S1A–C). The baseline CTC number 
group is predictive for response to CCRT and locoregional or distant failure with P values of 0.001 and 0.027, 
respectively, by the chi-square test (Supplementary Table S2). In further analysis, the CTCR score was found to 
be able to significantly differentiate patients with advanced EC into groups with distinct OS after first response 
evaluation (Fig. 3d and Supplementary Figure S1D). However, there was no clear correlation among CTC number 
and clinical T stage (P = 0.088), N stage (P = 0.164), and initial M status (P = 0.400) by the chi-square test (Table 
not shown).
Discussion
This study firstly demonstrated an overall recovery rate of 44.6 ± 9.1% and a %CV of 20.4% using a simple, cheap, 
and widely available CTC analysis method with Ficoll isolation and CD45 depletion by magnetic beads fol-
lowed by flow cytometry for detection. The detection rate of CTCs was 100.0% and a cutoff of 21.0 cells/mL was 
obtained by ROC curve (P = 0.04). Not surprisingly, the initial staging, surgery after CCRT, and the response to 
CCRT contributed to the OS of ESCC patients with statistical significance. (P < 0.0001, < 0.0001, and < 0.0001, 
respectively) Taking into consideration of all the above factors, the pre-CCRT CTC number showed its independ-
ent prognostic impact on disease-specific PFS and OS with hazard ratios (HRs) (95% confidence interval [CI]) of 
3.113 (1.427–6.791) and 1.002 (1.000–1.004), respectively. In addition, the CTCR score, which was first proposed 
in the literature, could clearly separate the OS with statistical significance (P < 0.001), by considering both the 
CTC category (low, high) and responses (CR, PR, SD + PD). The CTCR score might be able to provide group 
selection in future clinical trials. To the best of our knowledge, this is the first report using a negative selection 
Figure 3. The number of circulating tumour cells (CTCs) can differentiate oesophageal cancer patients 
and its impact on survival. The method of circulating tumour cell (CTC) detection can differentiate healthy 
individuals from patients with advanced oesophageal cancer with a P value of 0.04 using the Mann-Whitney U 
test (Panel A). Panels B and C show that patients with a lower pre-treatment CTC number have longer disease-
specific progression-free survival or overall survival. Given the CTC status (score zero for CTC number less 
than 21.0 cells/mL; 1 for CTC number ≥ 21.0 cells/mL) and response after concurrent chemoradiotherapy 
(CCRT, score zero for complete remission; 1 for partial response; 2 for stable disease, and 3 for progressive 
disease), the summation of the CTC score and the score of response to CCRT is defined as the circulating 
tumour cell plus response (CTCR) score, and this score highly correlates with overall survival with a log rank 
test P value of < 0.0001.
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strategy combined with flow cytometry to perform CTC analysis in advanced ESCC patients who underwent 
CCRT that proved the independent prognostic role of CTCs.
In the literature, there are only a few studies that address the role of CTCs in EC patients. Table 3 summarizes 
the most important information from these studies. In 2002, Koike, M. et al. reported the first work using reverse 
transcription-polymerase chain reaction (RT-PCR) to detect tumour-specific carcinoembryonic antigen (CEA) 
messenger RNA (mRNA) in the circulation and concluded that the CEA mRNA measured by RT-PCR could be 
more sensitive than conventional serum tumour markers (CEA and squamous cell carcinoma [SCC])39. Also uti-
lizing RT-PCR, Nakashima, S. et al. found in 2003 that CEA mRNA detection could predict cancer recurrence40. 
In the following year, Ito et al. found that CEA combined with cytokeratin 20 (CK20) mRNA (CEA assay) could 
also predict tumour recurrence better than serum tumour markers41. In 2007, Ikoma, D. et al. used multiple 
mRNAs, including CEA, p16, E-cadherin, and retinoic acid receptor (RAR) to monitor EC cancer after curative 
surgery. In the same year, Liu, Z. et al. used CEA mRNA from peripheral blood cells in a Chinese population 
to prove that the CEA mRNA expression detected by RT-PCR could predict distant metastasis in EC patients 
who underwent curative surgery42. In addition to patients with resectable tumours, Yin, X. D. et al. chose EC 
patients scheduled to undergo radical radiotherapy, and reported that the detection of CEA+ CK19+ survivin 
mRNA by RT-PCR could be a promising biomarker for radiation efficiency and assessment of prognosis. Until 
2012, RT-PCR for tumour-specific mRNA was the main method for CTC detection. However, cancer cells were 
not actually captured in these studies, and cancer-specific mRNA expression might not truly correlate with the 
cancer cell count in the circulation. In 2014, Bobek, V. et al. from the Czech Republic reported on an interesting 
device utilising a size-based mechanism to literally capture CTCs43. The report concluded that the method could 
capture CTCs and prove that these cells are alive for further cultivation. This was a novel and important finding, 
but no clinical relevance was reported with the use of this device. The CellSearch® system (Janssen Diagnostics, 
LLC, Raritan, NJ, USA), an FDA-approved device using a positive selection strategy to identify CTCs, was used 
by three groups, Matsushitam et al. Reeh et al. and Tanaka et al., and the correlations with treatment response and 
an independent prognostic role of CTCs were impressive26,44,45. However, one of the drawbacks of the Cellsearch® 
system was its known detection rate, suggesting a possible loss of CTC information. Furthermore, performing 
CTCs analysis with the CellSearch® system is relatively costly and device-dependent. Theoratically, our method, 
utilising negative depletion of CD45+ cells and positive selection of EpCAM and cytokeratins with flow cytom-
etry, is capable of providing clinicians and medical researchers a much easier and cheaper platform to conduct 
CTC-related clinical trials. Moreover, our study focused on patients with unresectable or metastatic status, a 
group seldom investigated in the literature.
One subject we should particularly discuss is that the survival of enrolled patients in our study was relatively 
short when compared with that of the general EC population. Several plausible reasons include, firstly, the fact that 
the study only enrolled Asian patients with ESCC and that 38.6% of the patients were classified as ECOG PS ≥ 2, 
which means that the status of the population could be worse than that of general, locally advanced EC patients. 
Secondly, there are some differences amongst Western and Asian patients with EC, including major histological 
types, risk factors, male-to-female ratio, and clinical outcomes. In comparison with Western countries, the major 
histology in Asian EC patients is still SCC, and this accounts for 91.5% of EC patients in Taiwan46, while in some 
areas of the United States, up to 60% of patients are diagnosed with AC1. Poor outcomes in Taiwanese patients could 
be explained as a result of relatively low socioeconomic status and exposure to multiple carcinogens, including 
Prognostic 
Factors
Disease-specific Progression-free Survival Overall Survival
Univariate Multivariate Univariate Multivariate
HR for 
PD (95% CI) P value
HR for 
PD (95% CI) P value
HR for 
death (95% CI) P value
HR for 
death (95% CI) P value
Age, (yr)
 ≥ 50 vs. < 50 1.108 (0.558–2.199) 0.770 0.930 (0.510–1.697) 0.814
Surgery after CCRT
 Yes vs. No 0.142 (0.049–0.413) < 0.001 0.160 (0.052–0.486) 0.001 0.189 (0.079–0.455) < 0.001 0.19 (0.076–0.472) < 0.001
ECOG PS
 0–1 vs.≥ 2 0.604 (0.286–1.272) 0.185 0.296 (0.157–0.556) < 0.001 0.276 (0.138–0.553) < 0.001
TNM Stage (7th 
ed.) < 0.001 < 0.001 0.001 0.003
 Stage II 0.072 (0.009–0.591) 0.014 0.041 (0.004–0.388) 0.005 0.077 (0.010–0.612) 0.015 0.112 (0.013–0.944) 0.044
 Stage III 0.210 (0.094–0.470) < 0.001 0.186 (0.077–0.452) 0.000 0.310 (0.154–0.626) 0.001 0.306 (0.147–0.636) 0.002
 Stage IV reference reference reference reference
CTC number (cells/mL)
 ≥ 21.0 vs. < 21.0 2.022 (1.010–4.049) 0.047 3.113 (1.427–6.791) 0.004 2.661 (1.375–5.150) 0.024
CTC number 
(cells/mL) 1.002 (0.999–1.004) 0.139 1.003 (1.001–1.005) 0.002 1.002 (1.000–1.004) 0.028
Table 2.  Univariate and Multivariate Analysis for Survivals. Abbreviations: HR, hazard ratio; CI, confidence 
interval; PD, progressive disease; CCRT, concurrent chemoradiotherapy; ECOG PS, Eastern Cooperative Group 
performance status; CTC, circulating tumour cells.
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cigarettes, alcohol, and betel nut chewing47. Thirdly, the male-to-female ratio (27.5 to 1) in our study is not com-
parable to that of the general EC population, which might partially explain the short survival in this study. More 
specifically, the male-to-female ratio is approximately 13.57 to 14 according to the Taiwan Cancer Registry data-
base, whereas a ratio of 3 to 1 is commonly noted in Western countries1,2. The phenomenon of male populations 
harbouring worse outcomes than those for women has also been noticed in some southern European countries2. 
These reasons could explain the short survival, but would not confuse the role of CTCs after statistical adjustment.
Although the current study successfully demonstrated the correlations among the number of CTCs, 
the disease-specific PFS and OS, and the cutoff of CTCs with clinical impact, these could change with differ-
ent methods of CTC detection. In fact, different methods would yield different recovery rates and purity. We 
should note that the CTC number obtained by different methods should not be compared for clinical signifi-
cance. Furthermore, the cutoff value with one type of CTC detection method is different from another. That is, 
the concept of a “low” or “high” CTC number would be relatively adequate rather than setting a definite CTC 
number cutoff for all solid tumours. In the present study, an easy-to-perform, controlled, cheap, and commonly 
available method is proposed to help foster the availability of CTC studies in every medical laboratory. Sample 
loss could be a problem with this method, but this could be overcome through careful procedures conducted by 
well-trained technicians. Although we found a cutoff to separate EC patients into two groups with survival dif-
ference, the relatively small sampling size limited the accuracy of the cutoff in this pilot study. In the near future, 
a satisfactory cutoff value will possibly be decided upon after the collection of large-scale information using 
one single method with similar controls. Possible reasons that could explain the false positivity of this method 
Author Year Country Patient Group N (Detection Rate)
Methods of CTC 
Analysis Major Results
Molecular detection
 Koike, M. et al. 2002 Japan Resectable, mainly 43 (53.5%) RT-PCR for Np63 mRNA
More sensitive than SCC and 
CEA
 Nakashima, S. et al. 2003 Japan Resectable 54 (54.7%) RT-PCR for CEA mRNA
More predictive of tumour 
recurrence than serum tumour 
markers
 Ito, H. et al. 2004 Japan All stages 28 (25.0–57.9%)
RT-PCR for 
CEA+ CK20 
mRNA (CEA 
assay)
A reliable means of predicting 
early recurrence.
 Ikoma, D. et al. 2007 Japan Resectable 44 (53.0%)
RT-PCR for CEA, 
p16, E-cadherin, 
RAR mRNA
Can serve as complementary 
markers for screening and 
monitoring oesophageal cancer 
patients
 Liu, Z. et al. 2007 China Resectable 53 (28.3–60.4%) RT-PCR for CEA mRNA
Operation results in tumour cell 
dissemination and significant 
increase of CTCs in peripheral 
blood, which is related to the 
developed metastasis
 Yin, X. D. et al. 2012 China Radical radiotherapy 72 (38.9–54.2%)
RT-PCR for 
CEA+ CK19+ 
survivin mRNA
Positive detection of CTCs 
in patients with ESCC after 
radiotherapy may be a promising 
biomarker for radiation efficiency 
and assessment of prognosis 
Physical Strategy (Size or Filter)
 Bobek, V. et al. 2014 Czech Resectable 43 (62.8%)
size-based 
filtration, 
CK18(+ )
Successful culturing of 
oesophageal cancer CTCs
Immunomagnetic Isolation (Positive or Negative Strategy)
 Matsushitam D. et al. 2015 Japan
Resecatble and 
unresecatble cases, CT 
or CCRT
90 (27.8%)
CellSearch 
(positive 
selection)
CTCs correlate to treatment 
response, prognostic factor(+ )
 Reeh, M. et al. 2015 Germany Resectable, no CT or CCRT 123 (18%)
CellSearch 
(positive 
selection)
Independent, prognostic 
indicators of patients’ outcome in 
EC; implementation of CTCs may 
improve accuracy of preoperative 
staging in EC
 Tanaka et al. 2015 Japan Unresectable, CT or CCRT 38 (50%)
CellSearch 
(positive 
selection)
CTCs can be useful for predicting 
the survival and for monitoring 
the treatment response
 Su, P. J. et al. 2016 Taiwan Unresectable, All CCRT 57 (100.0%)
Negative selection 
(CD 45 depletion) 
+ Flow cytometry
Surgery after response to CCRT, 
ECOG PS, initial TNM stage, and 
CTC number are independent 
prognostic factors 
Table 3.  Mini-review of Circulating Tumour Cells in Oesophageal Cancer. Abbreviations: RT-PCR, reverse 
transcription polymerase chain reaction; CEA, carcinoembryonic antigen; mRNA, messenger ribonucleic 
acid; CK, cytokeratin; CTC, circulating tumour cells; ESCC, oesophageal squamous cell carcinoma; CT, 
chemotherapy; CCRT, concurrent chemoradiotherapy; EC, oesophageal carcinoma; ECOG PS, Eastern 
Cooperative Oncology Group performance status.
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include the background noise or non-significant epithelial cells in the circulation, and further long-term obser-
vations for these patients are still needed. Another confirmation method may be possible with the sequencing of 
cancer-specific DNA mutations on CTCs to avoid bias. Although the technique of DNA mutation detection on 
CTCs has been proposed, it still seems to be highly technique-dependent48,49.
There are still some limitations of this study to discuss. Firstly, patients with T4b cancer and those with cervical 
EC were enrolled in this study, which could contribute some bias. These patients would not undergo surgery due to 
their disease status even with the achievement of PR after CCRT. One other problem was the fact that some patients, 
mostly of cT4b status, who died of sudden massive tumour bleeding and/or sepsis from tracheoesophageal fistula 
during CCRT, caused shortening of the survival in this study. Secondly, the Cellsearch® system can generate a detec-
tion rate (≧ 5 cells/7.5 mL blood) of 0~48%50, a recovery rate of 80~82%51 and an inter-laboratory % CV of 45~64%52. 
We admit that our recovery rateof our protocol was lower than Cellsearch®; however, our protocol was designed to 
be very easily obtained and performed. The relatively low recovery was probably resulted from Ficoll separation 
procedure which lost a part of CTCs53, but it could separate red blood cells completely and allow further molecular 
analysis to proceed. Nevertheless, given consideration of these conditions, CTCs could still play an important role in 
patients with EC. Further studies on females or patients with EAC in the Asian population are warranted.
In conclusion, we attempted to develop, validate, and report on an easy-to-use platform for CTC analysis that 
is mostly available in medical laboratories. The CTC number before CCRT was proven to be an independent 
prognostic factor in patients with unresectable ESCC. However, as with many proof-of-concept reports, further 
large-scale prospective studies to determine a better cutoff value are warranted.
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